ClinicalTrials.gg
CompletedNCT00903422Updated Nov 13, 2017

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

A Phase 1 interventional study of eltrombopag olamine and Placebo in Myelodysplastic Syndrome, sponsored by GlaxoSmithKline. Completed at 65 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-13.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing eltrombopag in Myelodysplastic Syndromes — none open to participants now, 2 under way, none of them phase 3. eltrombopag · Myelodysplastic Syndromes.

Enrollment
4th of 13
98 · median 30
Started
2009
the only one that year
Phase 1
3 of 13
none open now
Registered
1st of 13
by date
Lead sponsor
1 of 13
GlaxoSmithKline

Among the 13 studies testing eltrombopag in Myelodysplastic Syndromes, this one is the 4th largest by enrollment, is the only one that started in 2009, is one of 3 in phase 1, and was the 1st registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

None of the 13 studies testing eltrombopag in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing eltrombopag in Myelodysplastic Syndromes as a file.
02

Study summary

This study will evaluate the safety and tolerability of eltrombopag in the treatment of low platelet counts in adult subjects with advanced myelodysplastic syndrome (MDS), secondary acute myeloid leukemia after MDS (sAML/MDS), or de novo AML that are relapsed, refractory or ineligible to receive azacitidine, decitabine, intensive chemotherapy or autologous/allogeneic stem cell transplantation. This is a placebo-controlled study in which patients will receive study medication daily for 6 months, during which time the dose of study medication may be adjusted based upon individual platelet counts and bone marrow blast counts. All subjects will receive best standard of care (platelet transfusions, mild chemotherapy, cytokines, valproic acid, all-trans retinoic acid, ESAs or G-CSF) in addition to study medication. Subjects taking placebo may be allowed to crossover to eltrombopag treatment if a clinically and statistically significant improvement in bone marrow blast counts is seen in subjects treated with eltrombopag.

Read the detailed description

A double-blind, randomized, placebo-controlled phase I/II study to evaluate the safety and tolerability of eltrombopag olamine, a thrombopoietin receptor agonist, administered for 6 months as oral tablets once daily in adult subjects with advanced MDS, sAML/MDS, or de novo AML. Study medication may be increased up to 300 mg (150 mg maximum dose for East Asian subjects), based upon individual platelet counts and bone marrow blast counts.

03

Conditions studied

  • Myelodysplastic Syndrome

Keywords

  • Advanced Myelodysplastic Syndrome
  • Thrombocytopenia
  • sAML/MDS
  • Eltrombopag
  • TPO-R agonist
  • de novo AML
  • Thrombopoietin
  • MDS
  • Thrombopoietin receptor agonist
  • secondary Acute Myeloid Leukemia after MDS
  • Platelets
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects (18 years of age or older) with advanced MDS, sAML/MDS, or de novo AML with >=10% and \<=50% blasts in bone marrow. Peripheral blood blast change over time should not be suggestive of highly proliferative disease (as judged by the investigator).
  • Subjects must be dependent on regular transfusions or have a platelet count taken within the 4 weeks prior to randomization that is \<30 Gi/L.
  • Subjects must be , refractory or ineligible to receive standard treatment options of azacitidine and decitabine and must be relapsed, refractory or ineligible to receive intensive chemotherapy or /allogeneic stem cell transplantation. A subject may be considered relapsed/refractory to a standard treatment if it is discontinued due to lack of efficacy. For subjects ineligible for standard treatments, it is permissible to start one of these standard treatments while on study medication if the Investigator considers that the subject becomes eligible during the course of the study.
  • Prior therapy with demethylating agents (azacitidine or decitabine), lenalidomide or IL-11(oprelvekin) must have been completed at least 4 weeks before Day 1; antithymocyte/antilymphocyte globulin, intensive chemotherapy, or autologous/allogeneic stem cell transplantation must have been completed at least 2 months before Day 1. If a subject must discontinue a course of therapy due to lack of efficacy, the listed above do not apply (and the patient may be screened and randomized immediately if other eligibility criteria are met).
  • Subjects must have platelet count and platelet transfusion data available over a period of 4 weeks prior to randomization.
  • Subjects with advanced MDS, sAML/MDS, or de novo AML must have stable disease indicated by a doubling time of peripheral blast counts >7 days during screening.
  • During the 4 weeks prior to randomization, subjects must have a baseline bone marrow examination including the following:
  • cytomorphology to confirm bone marrow blasts between 10-50%,
  • cytogenetics (provide only most prevalent abnormal clone),

The results of the above tests are required prior to subject randomization.

  • Supportive/palliative therapies such as cytokines (except for IL-11; oprelvekin), valproic acid, all-trans retinoic acid or mild chemotherapy are allowed if part of the local SOC, provided those therapies have been at a stable dose for 4 weeks. If the subject chooses to discontinue these therapies prior to study entry, they must be completed 4 weeks prior to enrollment into this study, unless the therapy is discontinued due to lack of efficacy. Erythropoiesis-stimulating agents (ESAs) in anemic subjects or granulocyte colony-stimulating factor (G-CSF) in subjects with severe neutropenia and recurrent infections are allowed during the study as per accepted standards. Subjects who enter the study on ESAs or G-CSF should continue at the same dose schedule until the optimal dose of study medication has been established.
  • Status 0-3.
  • Subject is able to understand and comply with protocol requirements and instructions.
  • Subject has signed and dated .
  • (PT/INR) and activated partial thromboplastin time (aPTT) must be within 80 to 120% of the normal range at baseline.
  • Adequate baseline organ function defined by the criteria below:
  • total (except for Gilbert's Syndrome) \<= 1.5xULN
  • and AST \<= 3xULN
  • creatinine \<= 2xULN
  • albumin must not be below the lower limit of normal (LLN) by more than 20%.
  • Subject is practicing an acceptable method of (documented in chart). Female subjects (or female partners of male subjects) must either be of non- (hysterectomy, bilateral oophorectomy, bilateral tubal ligation or >1 year), or of childbearing potential and use 1 of the following highly effective methods of contraception (i.e., Pearl Index \<1.0%) from 2 weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study:
  • Complete abstinence from intercourse;
  • Intrauterine device (IUD);
  • Two forms of barrier contraception (diaphragm plus spermicide, and for males condom plus spermicide);
  • Male partner is sterile prior to entry into the study and is the only partner of the female;
  • Systemic contraceptives (combined or progesterone only).

Exclusion criteria

Exclusion Criteria:

  • Subjects with a diagnosis of acute promyelocytic leukemia.
  • History of treatment for cancer (other than MDS, sAML/MDS, or de novo AML) with systemic chemotherapy and/or radiotherapy within the last 2 years.
  • History of treatment with romiplostim or other TPO-R agonists.
  • Pre-existing cardiovascular disease (including congestive heart failure, [NYHA] Grade III/IV), or arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation), or subjects with a >450 msec (QTc >480 msec for subjects with Bundle Branch Block).
  • Bone marrow fibrosis that leads to an inability to aspirate marrow for assessment.
  • Spleen size >14 cm (length as per ultrasound examination).
  • Leukocytosis >=25,000/uL prior to Day 1 of study medication.
  • Female subjects who are nursing or pregnant (positive serum or urine Beta-human chorionic gonadotropin [B-hCG] pregnancy test) at screening or pre-dose on Day 1.
  • Current alcohol or drug abuse.
  • Treatment with an drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
  • Active and uncontrolled infections.
  • Subjects infected with , C or (HIV).
  • Subjects with liver cirrhosis.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
98 participants (actual)

Study arms

  • Active comparator
    Eltrombopag

    Eltrombopag

    Drug: eltrombopag olamine

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • thrombopoietin receptor agonist

  • OtherPlacebo

    Placebo tablets with no active pharmaceutical ingredient

06

What researchers measure

Primary outcomes

  1. Safety and tolerability parameters including non-hematological laboratory Grade 3/Grade 4 toxicities, change in bone marrow blast counts from baseline and adverse events reporting.

    Time frame: Approximately 46 months

Secondary outcomes

  1. Proportion of subjects with a baseline platelet count <20 Gi/L and an increase to >20 Gi/L and by at least 2x baseline; or a baseline platelet count between >=20-<30 Gi/L and an absolute platelet count increase to >=50 Gi/L at any time during treatment.

    Time frame: Approx. 46 months

  2. Frequency and number of units of platelet transfusions during the treatment and follow-up periods for eltrombopag- and placebo-treated subjects.

    Time frame: approx 46 months

  3. The incidence and severity of bleeding events, measured using the World Health Organization (WHO) Bleeding Scale, during the treatment and 4 week follow-up periods for eltrombopag- and placebo-treated subjects.

    Time frame: approx. 46 months

  4. Overall survival (OS) of eltrombopag- and placebo-treated subjects.

    Time frame: approx. 46 months

  5. Change in health-related quality of life as measured using the EQ-5D questionnaire.

    Time frame: approx. 46 months

07

Study locations

65 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294, United States
  • GSK Investigational Site
    Santa Monica, California 90404, United States
  • GSK Investigational Site
    Stanford, California 94305, United States
  • GSK Investigational Site
    Coral Springs, Florida 33065, United States
  • GSK Investigational Site
    Lake Worth, Florida 33467, United States
  • GSK Investigational Site
    Atlanta, Georgia 30341, United States
  • GSK Investigational Site
    Baltimore, Maryland 21231, United States
  • GSK Investigational Site
    Boston, Massachusetts 02111, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Kansas City, Missouri 64128, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63110, United States
  • GSK Investigational Site
    Camden, New Jersey 08103, United States
  • GSK Investigational Site
    The Bronx, New York 10461, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19106, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15224, United States
  • GSK Investigational Site
    Greenville, South Carolina 29601, United States
  • GSK Investigational Site
    Memphis, Tennessee 38120, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    New Braunfels, Texas 78130, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Arlington, Virginia 22205, United States
  • GSK Investigational Site
    Fairfax, Virginia 22031, United States
  • GSK Investigational Site
    Madison, Wisconsin 53705, United States
  • GSK Investigational Site
    Salvador, Bahía 41253-190, Brazil
  • GSK Investigational Site
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 20211-030, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 20230 -130, Brazil
  • GSK Investigational Site
    Koebenhavn Oe, 2100, Denmark
  • GSK Investigational Site
    Odense C, 5000, Denmark
  • GSK Investigational Site
    Bayonne cedex, 64109, France
  • GSK Investigational Site
    Besançon cedex, 25030, France
  • GSK Investigational Site
    Bobigny Cedex, 93009, France
  • GSK Investigational Site
    Caen cedex 9, 14033, France
  • GSK Investigational Site
    Marseille cedex 9, 13273, France
  • GSK Investigational Site
    Paris Cedex 12, 75571, France
  • GSK Investigational Site
    Toulouse, 31059, France
  • GSK Investigational Site
    Stuttgart, Baden-Wuerttemberg 70199, Germany
  • GSK Investigational Site
    Ulm, Baden-Wuerttemberg 89081, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81675, Germany
  • GSK Investigational Site
    Goettingen, Niedersachsen 37075, Germany
  • GSK Investigational Site
    Duesseldorf, Nordrhein-Westfalen 40225, Germany
  • GSK Investigational Site
    Duisburg, Nordrhein-Westfalen 47166, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 50937, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55131, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01307, Germany
  • GSK Investigational Site
    Berlin, 12200, Germany
  • GSK Investigational Site
    Hong Kong, Hong Kong
  • GSK Investigational Site
    Shatin, New Territories, Hong Kong
  • GSK Investigational Site
    Reggio Calabria, Calabria 89100, Italy
  • GSK Investigational Site
    Firenze, Toscana 50134, Italy
  • GSK Investigational Site
    Vicenza, Veneto 36100, Italy
  • GSK Investigational Site
    Seoul, 135-710, Korea, Republic of
  • GSK Investigational Site
    Seoul, 137-701, Korea, Republic of
  • GSK Investigational Site
    Seoul, 138-736, Korea, Republic of
  • GSK Investigational Site
    San Juan, 00927, Puerto Rico
  • GSK Investigational Site
    Changhua, 500, Taiwan
  • GSK Investigational Site
    Taichung, 404, Taiwan
  • GSK Investigational Site
    Taipei, 100, Taiwan
  • GSK Investigational Site
    Taipei, 112, Taiwan
  • GSK Investigational Site
    Aberdeen, AB25 2ZN, United Kingdom
  • GSK Investigational Site
    Glasgow, G12 0YN, United Kingdom
  • GSK Investigational Site
    Leeds, LS9 7TF, United Kingdom
  • GSK Investigational Site
    London, SE5 9RS, United Kingdom
  • GSK Investigational Site
    London, SW17 0RE, United Kingdom
08

References and documents

Publications

  • Mavroudi I, Pyrovolaki K, Pavlaki K, Kozana A, Psyllaki M, Kalpadakis C, Pontikoglou C, Papadaki HA. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res. 2011 Mar;35(3):323-8. doi: 10.1016/j.leukres.2010.06.029. Epub 2010 Aug 4. PubMed 20688394 ↗
  • Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Gotze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol. 2015 Oct;2(10):e417-26. doi: 10.1016/S2352-3026(15)00149-0. Epub 2015 Oct 1. PubMed 26686043 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2009 to primary completion in Jun 2012, 37 months.

Of 84 industry-sponsored phase 1 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 37 months is below that.

Counting every sponsor, half of 220 studies reached it within 52 months; a quarter within 31 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2009
First posted
May 18, 2009
StartActual
May 14, 2009
Primary completionActual
Jun 26, 2012
CompletionActual
Dec 5, 2013
Last update
Nov 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00903422
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 18, 2009
Start date
May 14, 2009
Primary completion
Jun 26, 2012
Completion
Dec 5, 2013
Last update
Nov 13, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion